Table 1.
Antimicrobial susceptibility of P. aeruginosa clinical isolates obtained from patients at a hospital center in China, 2012–2017
| Antimicrobial | All isolates (n=2,241)
|
MDR (n=414)
|
XDR (n=78)
|
||||||
|---|---|---|---|---|---|---|---|---|---|
| MIC (μg/mL)
|
Range of values
|
Breakpoint interpretationsa
|
|||||||
| MIC50 | MIC90 | Min | Max | %S | %I | %R | %S | %S | |
| Amikacin | 4 | 16 | ≤1 | >64 | 76.07 | 1.71 | 22.22 | 56 | 24.5 |
| Ceftazidime | 4 | 32 | ≤0.25 | >32 | 74.82 | 7.7 | 17.48 | 20.4 | 0 |
| Ciprofloxacin | 0.25 | 4 | ≤0.06 | >16 | 73 | 10.1 | 16.9 | 23 | 0 |
| Colistin | 1 | 2 | ≤0.06 | >16 | 99.6 | 0 | 0.4 | 98.41 | 95.6 |
| Gentamicin | 2 | 8 | ≤0.5 | >32 | 68.4 | 2.59 | 29.01 | 45.1 | 1.3 |
| Meropenem | 0.5 | 8 | ≤0.03 | >32 | 76.55 | 6.2 | 17.25 | 71 | 67 |
| Piperacillin/tazobactam | 4 | 64 | ≤1 | >128 | 81.07 | 5.11 | 13.82 | 22.3 | 0 |
| Cefoperazone/sulbactam | 4 | 64 | ≤1 | >128 | 76.4 | 17.49 | 6.11 | 70.35 | 69 |
| Imipenem | 0.5 | 8 | ≤0.03 | >32 | 71.23 | 8.85 | 19.92 | 60 | 65 |
| Tigecycline | 1 | 2 | ≤0.06 | >16 | 98.83 | 0 | 1.17 | 94 | 91 |
Notes:
%S = %susceptible, %I = %intermediate, %R = %resistant; breakpoint interpretation: amikacin S≤16 μg/mL, I=32 μg/mL, R≥64 μg/mL; ceftazidime S≤8 μg/mL, I=16 μg/mL, R≥32 μg/mL; ciprofloxacin S≤1 μg/mL, I=2 μg/mL, R≥4 μg/L; colistin S≤2 μg/mL, I=4 μg/mL, R≥8 μg/mL; gentamicin S≤4 μg/mL, I=8 μg/mL, R≥16 μg/mL; meropenem S≤2 μg/mL, I=4 μg/mL, R≥8 μg/mL; piperacillin/tazobactam S≤16/4 μg/mL, I=32/4 μg/mL, R≥128/4 μg/mL; cefoperazone/sulbactam S≤16/4 μg/mL, I=32/4 μg/mL, R≥128/4 μg/mL; imipenem S≤2 μg/L, I=4 μg/mL, R≥8 μg/mL; tigecycline S≤2 μg/mL, I=4 μg/mL, R≥8 μg/mL.
Abbreviations: Max, maximum; MDR, multidrug resistant; Min, minimum; MIC, minimum inhibitory concentration; P. aeruginosa, Pseudomonas aeruginosa; XDR, extensively drug resistant.